Phuong N. Huynh

Array ( [id] => 5443065 [patent_doc_number] => 20090094704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-09 [patent_title] => 'Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84' [patent_app_type] => utility [patent_app_number] => 12/286620 [patent_app_country] => US [patent_app_date] => 2008-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 4908 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0094/20090094704.pdf [firstpage_image] =>[orig_patent_app_number] => 12286620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5545378 [patent_doc_number] => 20090155255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-18 [patent_title] => 'CD23 BINDING MOLECULES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/240880 [patent_app_country] => US [patent_app_date] => 2008-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 49628 [patent_no_of_claims] => 72 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0155/20090155255.pdf [firstpage_image] =>[orig_patent_app_number] => 12240880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5429099 [patent_doc_number] => 20090088409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-02 [patent_title] => 'SERUM BIOMARKERS FOR EARLY DETECTION OF ACUTE CELLULAR REJECTION' [patent_app_type] => utility [patent_app_number] => 12/235292 [patent_app_country] => US [patent_app_date] => 2008-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11975 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20090088409.pdf [firstpage_image] =>[orig_patent_app_number] => 12235292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15054861 [patent_doc_number] => 10457719 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof [patent_app_type] => utility [patent_app_number] => 12/678494 [patent_app_country] => US [patent_app_date] => 2008-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21978 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12678494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6292681 [patent_doc_number] => 20100239596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-23 [patent_title] => 'GRP78 AND TUMOR ANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 12/674583 [patent_app_country] => US [patent_app_date] => 2008-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12388 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20100239596.pdf [firstpage_image] =>[orig_patent_app_number] => 12674583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5367160 [patent_doc_number] => 20090304719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/196269 [patent_app_country] => US [patent_app_date] => 2008-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 40524 [patent_no_of_claims] => 144 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0304/20090304719.pdf [firstpage_image] =>[orig_patent_app_number] => 12196269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5421947 [patent_doc_number] => 20090148402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-11 [patent_title] => 'THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/193582 [patent_app_country] => US [patent_app_date] => 2008-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31747 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0148/20090148402.pdf [firstpage_image] =>[orig_patent_app_number] => 12193582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5527774 [patent_doc_number] => 20090197851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-06 [patent_title] => 'THERAPY AND USE OF COMPOUNDS IN THERAPY' [patent_app_type] => utility [patent_app_number] => 12/187169 [patent_app_country] => US [patent_app_date] => 2008-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 20292 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0197/20090197851.pdf [firstpage_image] =>[orig_patent_app_number] => 12187169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6228778 [patent_doc_number] => 20100183516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 12/670565 [patent_app_country] => US [patent_app_date] => 2008-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 109 [patent_no_of_words] => 30979 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12670565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6504234 [patent_doc_number] => 20100260765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-14 [patent_title] => 'TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035' [patent_app_type] => utility [patent_app_number] => 12/669724 [patent_app_country] => US [patent_app_date] => 2008-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 61673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0260/20100260765.pdf [firstpage_image] =>[orig_patent_app_number] => 12669724 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6528948 [patent_doc_number] => 20100015158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-21 [patent_title] => 'METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION' [patent_app_type] => utility [patent_app_number] => 12/176238 [patent_app_country] => US [patent_app_date] => 2008-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11914 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20100015158.pdf [firstpage_image] =>[orig_patent_app_number] => 12176238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6468542 [patent_doc_number] => 20100190957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-29 [patent_title] => 'SPECIFIC THERAPY AND MEDICAMENT USING INTEGRIN LIGANDS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 12/668823 [patent_app_country] => US [patent_app_date] => 2008-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 57703 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0190/20100190957.pdf [firstpage_image] =>[orig_patent_app_number] => 12668823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4560935 [patent_doc_number] => 07846437 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-12-07 [patent_title] => 'Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same' [patent_app_type] => utility [patent_app_number] => 12/165446 [patent_app_country] => US [patent_app_date] => 2008-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 5 [patent_no_of_words] => 26535 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/846/07846437.pdf [firstpage_image] =>[orig_patent_app_number] => 12165446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 288816 [patent_doc_number] => 07547440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-06-16 [patent_title] => 'T-cell epitope peptides' [patent_app_type] => utility [patent_app_number] => 12/163896 [patent_app_country] => US [patent_app_date] => 2008-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5595 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/547/07547440.pdf [firstpage_image] =>[orig_patent_app_number] => 12163896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 122087 [patent_doc_number] => 07704498 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-04-27 [patent_title] => 'ErbB4 antagonists' [patent_app_type] => utility [patent_app_number] => 12/215200 [patent_app_country] => US [patent_app_date] => 2008-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 29371 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/704/07704498.pdf [firstpage_image] =>[orig_patent_app_number] => 12215200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6601467 [patent_doc_number] => 20100322939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-23 [patent_title] => 'NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS' [patent_app_type] => utility [patent_app_number] => 12/664258 [patent_app_country] => US [patent_app_date] => 2008-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10536 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0322/20100322939.pdf [firstpage_image] =>[orig_patent_app_number] => 12664258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5309730 [patent_doc_number] => 20090017011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-15 [patent_title] => 'MODULATION OF VEGF-C/VEGFR-3 INTERACTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 12/139102 [patent_app_country] => US [patent_app_date] => 2008-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17585 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0017/20090017011.pdf [firstpage_image] =>[orig_patent_app_number] => 12139102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5264443 [patent_doc_number] => 20090117128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-05-07 [patent_title] => 'Anti-HPA' [patent_app_type] => utility [patent_app_number] => 12/139086 [patent_app_country] => US [patent_app_date] => 2008-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5821 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20090117128.pdf [firstpage_image] =>[orig_patent_app_number] => 12139086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4634025 [patent_doc_number] => 08012473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-09-06 [patent_title] => 'C3b antibodies and methods for the prevention and treatment of complement-associated disorders' [patent_app_type] => utility [patent_app_number] => 12/157073 [patent_app_country] => US [patent_app_date] => 2008-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 19 [patent_no_of_words] => 27282 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/012/08012473.pdf [firstpage_image] =>[orig_patent_app_number] => 12157073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6270795 [patent_doc_number] => 20100254995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-07 [patent_title] => 'POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 12/663501 [patent_app_country] => US [patent_app_date] => 2008-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 91 [patent_figures_cnt] => 91 [patent_no_of_words] => 54927 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0254/20100254995.pdf [firstpage_image] =>[orig_patent_app_number] => 12663501 [rel_patent_id] =>[rel_patent_doc_number] =>)